beta

TRVN

Trevena, Inc.

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Trevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.

Market Cap: 56 Million

Primary Exchange: NASDAQ

Website: http://www.trevenainc.com

Shares Outstanding: 97.7 Million

Float: 87.3 Million

Dividend: (%)

Beta: 0.506980473527673

Sector: Health Technology

Industry: Biotechnology

Ethical Flags

Longest drawdown: 2143 trading days

From: 2015-09-18 To: 2020-03-27

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud